Medartis Holding AG / Key phrase(s): Personnel
11-Dec-2020 / 06:59 CET/CEST
Launch of an advert hoc announcement pursuant to Artwork. 53 KR
The issuer is solely liable for the content material of this announcement.
Medartis Holding AG
Medartis appoints Dirk Kirsten as Chief Monetary Officer
Basel, Switzerland, 11 December 2020 – The Board of Administrators of Medartis Holding AG (SIX: MED) has appointed Dirk Kirsten as new Chief Monetary Officer and Member of the Govt Administration Board. He’ll be a part of Medartis as of 1 march 2021 and can succeed Dominique Leutwyler, who has determined to go away the corporate.
In his future position as CFO and Member of the Govt Administration Board of Medartis, Dirk Kirsten shall be liable for all issues of inner and exterior group monetary administration, in addition to for the group’s M&A initiatives, thus actively supporting additional development and envisaged portfolio expansions.
As a confirmed monetary knowledgeable with broad business expertise, Dirk Kirsten (1968) has a robust observe file in worldwide administration, company finance and M&A and held varied senior administration positions within the medtech, pharmaceutical and healthcare sectors. These included the roles as CFO of Nobel Biocare (2008-2013), Group Treasurer of Syngenta (2004-2008) and Head Group Funding & Capital Markets of Roche Holding (2002-2004). Previous to that, he labored with world funding banks, the place he specialised in healthcare transactions. In 2013, Dirk Kirsten based his personal advisory boutique specializing in M&A, non-public fairness in addition to start-up financing and enterprise improvement. Dirk Kirsten is a Swiss and German citizen. He holds a PhD in Administration & Economics from the College of Cologne and took part within the worldwide MBA program of the London Enterprise College.
During the last 20 years, Dominique Leutwyler has made a big contribution as CFO in constructing the pillars of Medartis on its means from a start-up to a listed firm with broad worldwide presence. He established and additional developed the group’s finance capabilities, provide chain and ICT operations and was moreover liable for the set-up of its manufacturing infrastructure and its 13 subsidiaries in addition to for varied useful M&A actions. He additionally lead-managed Medartis’ profitable IPO in 2018. He’ll stay in his place till the 2020 full-year outcomes publication on 10 March 2021. The Board of Administrators and Govt Administration Board remorse Dominique Leutwyler’s choice and are grateful to him for his in depth and profitable contributions in constructing Medartis to its present strengths. Medartis needs him each success for his future.
Head Company Providers
Medartis Holding AG
Telephone: +41 61 633 34 70
Based in 1997 and headquartered in Basel, Switzerland, Medartis is without doubt one of the world’s main producers and suppliers of medical units for surgical fixation of bone fractures for higher and decrease extremities in addition to for the craniomaxillofacial area. Medartis employs round 630 people throughout its 13 places, with merchandise provided in over 50 nations globally. Medartis is dedicated to offering surgeons and working theatre personnel with essentially the most revolutionary titanium implants and devices in addition to finest at school service. For extra data, please go to www.medartis.com.
This communication doesn’t represent a proposal or invitation to subscribe for or buy any securities of Medartis Holding AG. This publication might include sure forward-looking statements and assessments or intentions regarding the firm and its enterprise. Such statements contain sure dangers, uncertainties and different components which may trigger the precise outcomes, monetary situation, efficiency or achievements of the corporate to be materially totally different from these expressed or implied by such statements. Readers ought to subsequently not place reliance on these statements, significantly not in reference to any contract or funding choice. The corporate disclaims any obligation to replace these forward-looking statements, assessments or intentions. Additional, neither the corporate nor any of its administrators, officers, staff, brokers, counsel or advisers nor another individual makes any illustration or guarantee, specific or implied, as to, and accordingly no reliance must be positioned on, the accuracy or completeness of the knowledge contained herein or of the views given or implied.
Finish of advert hoc announcement